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Abstract
Background: Atypical antipsychotic medications are widely prescribed for the adjunctive treatment of depression, yet their
total risk–benefit profile is not well understood. We thus conducted a systematic review of the efficacy and safety profiles of
atypical antipsychotic medications used for the adjunctive treatment of depression.
Methods and Findings: We included randomized trials comparing adjunctive antipsychotic medication to placebo for treatmentresistant depression in adults. Our literature search (conducted in December 2011 and updated on December 14, 2012) identified 14
short-term trials of aripiprazole, olanzapine/fluoxetine combination (OFC), quetiapine, and risperidone. When possible, we
supplemented published literature with data from manufacturers’ clinical trial registries and US Food and Drug Administration New
Drug Applications. Study duration ranged from 4 to 12 wk. All four drugs had statistically significant effects on remission, as follows:
aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48–2.73), OFC (OR, 1.42; 95% CI, 1.01–2.0), quetiapine (OR, 1.79; 95% CI, 1.33–2.42), and
risperidone (OR, 2.37; 95% CI, 1.31–4.30). The number needed to treat (NNT) was 19 for OFC and nine for each other drug. All
drugs with the exception of OFC also had statistically significant effects on response rates, as follows: aripiprazole (OR, 2.07; 95% CI,
1.58–2.72; NNT, 7), OFC (OR, 1.30, 95% CI, 0.87–1.93), quetiapine (OR, 1.53, 95% CI, 1.17–2.0; NNT, 10), and risperidone (OR, 1.83, 95%
CI, 1.16–2.88; NNT, 8). All four drugs showed statistically significant effects on clinician-rated depression severity measures (Hedges’ g
ranged from 0.26 to 0.48; mean difference of 2.69 points on the Montgomery–Asberg Depression Rating Scale across drugs). On
measures of functioning and quality of life, these medications produced either no benefit or a very small benefit, except for
risperidone, which had a small-to-moderate effect on quality of life (g = 0.49). Treatment was linked to several adverse events,
including akathisia (aripiprazole), sedation (quetiapine, OFC, and aripiprazole), abnormal metabolic laboratory results (quetiapine
and OFC), and weight gain (all four drugs, especially OFC). Shortcomings in study design and data reporting, as well as use of post
hoc analyses, may have inflated the apparent benefits of treatment and reduced the apparent incidence of adverse events.
Conclusions: Atypical antipsychotic medications for the adjunctive treatment of depression are efficacious in reducing
observer-rated depressive symptoms, but clinicians should interpret these findings cautiously in light of (1) the small-tomoderate-sized benefits, (2) the lack of benefit with regards to quality of life or functional impairment, and (3) the abundant
evidence of potential treatment-related harm.
Please see later in the article for the Editors’ Summary.
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published and unpublished studies for review, we searched
Medline, PsycINFO, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials using the terms depression AND
(aripiprazole OR asenapine OR clozapine OR iloperidone OR lurasidone
OR olanzapine OR paliperidone OR quetiapine OR risperidone OR
ziprasidone). Medline search results were restricted to the following
article types: clinical trial, controlled clinical trial, or randomized
controlled trial. Our literature search was conducted in December
2011 and updated on December 14, 2012. In addition, we
searched the American Psychiatric Association Annual Meeting
New Research Abstracts for 2001–2010 using each of the generic
drug names as a search term, then winnowed the results down to
abstracts that appeared to possibly meet the inclusion criteria. We
also examined all references in a previously published metaanalysis [6] as well as those contained in each published study
obtained through our literature search.
To obtain additional unpublished data, we searched the drug
manufacturers’ online clinical trial registries as well as FDA NDAs
for the atypical antipsychotic medications that have received an
indication for the adjunctive treatment of major depressive
disorder (aripiprazole, olanzapine-fluoxetine combination
[OFC], and quetiapine). For published studies, we supplemented
published data with data available in NDAs or clinical trial registry
reports whenever such data were available.

Introduction
Atypical antipsychotic medications are widely used in the
treatment of major depressive disorder. In the United States in
2007 and 2008, there were an estimated 3.9 million treatment visits
per year in which an antipsychotic medication was prescribed for
depression, and nearly all of these (96%) involved prescription of an
atypical antipsychotic medication [1]. Although aggregate statistics
mask the specific indications for use (i.e., monotherapy versus
adjunctive therapy), this represents a substantial increase in
antipsychotic treatment of depression over time, as there were just
over 2 million such visits annually during 1995 and 1996, of which
405,000 involved prescriptions for atypical antipsychotic medications. These data are also consistent with market reports from
industry [2]. Three atypical antipsychotic medications have
approval from the US Food and Drug Administration (FDA) as
adjunctive therapies in depression for adults, while none are
approved for monotherapy. These approvals (and subsequent
marketing efforts), along with the volume of prescriptions, suggest
that a large number of prescriptions for atypical antipsychotic
medications written for the treatment of depression are being used
for adjunctive therapy [3–5].
The efficacy of adjunctive atypical antipsychotic therapy in
reducing depression symptom severity in major depressive
disorder is summarized in two previous systematic reviews, but
neither comprehensively summarized data on both efficacy and
safety [6,7]. Both reviews analyzed efficacy only in terms of
dichotomous response and remission outcomes derived from
clinician-rated depression measures and did not assess changes in
terms of symptom severity on the underlying continuous rating
scales. Safety was only assessed by examining dropout rates due to
adverse events; the authors of these meta-analyses [6,7] and of a
relevant narrative review noted that a comprehensive summary of
safety data is lacking [8]. A Cochrane review provided a more
thorough assessment of both efficacy and safety outcomes but did
not include data on important patient-centered efficacy outcomes
such as patient-rated depression, functional impairment, or quality
of life [9]. The Cochrane review assessed the frequency of several
relevant adverse events, but some critical adverse events of
interest, such as elevated cholesterol or triglyceride levels, were not
included. Further, and most importantly, effect size estimates
presented in these reviews may have been inflated because the
authors did not summarize unpublished data, such as those from
FDA New Drug Applications (NDAs) or manufacturers’ clinical
trial registries [10–13]. Given the importance of functional status,
quality of life, and drug-related side effects to the overall
assessment of well-being and recovery from depressive mood
episodes [14–16], we conducted this meta-analysis to provide a
comprehensive estimate of the efficacy and safety profiles of
atypical antipsychotic medications for the adjunctive treatment of
major depressive disorder.

Study Selection
Trials were included if they were acute-phase (i.e., not for
relapse prevention or maintenance treatment [17,18]), placebocontrolled trials in which participants treated with antidepressant
medications were randomly assigned to additionally receive an
atypical antipsychotic medication or placebo. In order to meet our
definition of treatment-resistant depression, participants must have
been diagnosed with current major depressive disorder and must
have been determined to have had an inadequate response to at
least one course of antidepressant medication treatment prior to
enrollment in the study. Furthermore, data for at least one
outcome measure must have been reported in a manner that
allowed calculation of an effect size. No language exclusions were
applied.

Data Extraction
Four study authors (G. I. S., A. P., M. I. B., and E. L.) coded
study descriptor data. To establish consistency, all coders first
coded the articles reporting outcomes from the aripiprazole
studies. Then two study authors (G. I. S. and A. P.) jointly coded
the OFC and risperidone articles, and two study authors (M. I. B.
and E. L.) jointly coded the quetiapine articles. Disagreements
were resolved by consensus. Coders were not blind to the results of
the coded studies.
Several descriptor variables were coded for each study. (1)
Flexible dosing versus fixed dosing regimen. (2) Dosage range. (3)
Mean dosing achieved at end point. (4) Number of participants in
each group of trial. (5) Duration of acute-phase treatment (weeks).
(6) Number of prior failed trials of antidepressant medications,
where the number of failed trials prior to study enrollment
(historical) and the number of failed trials during the study
(prospective) prior to initiation of the study drug for adjunctive
treatment were recorded separately. (7) Procedures employed to
evaluate for major depressive disorder (structured interview or
otherwise). (8) Use of a structured instrument versus open-ended
questioning to elicit adverse events [19,20] (with the latter assumed
if no details were reported). (9) Adverse events scale(s) used to
systematically assess for any particular adverse event(s), if any. (10)

Methods
Ethical Review
Because this was a study-level systematic review and metaanalysis of trials, and did not involve collection and analysis of any
individual-level data, ethical approval was not sought for this
study.

Search Strategy
This systematic review was reported using PRISMA guidelines;
the PRISMA checklist is provided as Text S1. To identify both
PLOS Medicine | www.plosmedicine.org
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measures together to create an omnibus effect size for each drug,
and across all drugs.
We aggregated conceptually similar adverse events into the
following categories. (1) Sedation-related: asthenia, fatigue, lethargy, sedation, somnolence, or feeling tired. (2) Akathisia-related
(either self-reported or observer-rated): akathisia or restlessness. (3)
Extrapyramidal symptoms (EPS), other than akathisia-related
(either self-reported or observer-rated): dyskinesia, dystonia,
extrapyramidal disorder, EPS, muscle spasms, muscle twitching,
parkinsonism, or tremor. (4) Abnormal metabolic laboratory
results: elevated fasting or nonfasting total cholesterol, low-density
lipoprotein (LDL) cholesterol, or triglycerides; low high-density
lipoprotein (HDL) cholesterol; or elevated fasting or nonfasting
glucose, glycated hemoglobin; or hyperglycemia. (5) Elevated
prolactin. (6) Edema or peripheral edema. (7) Significant weight
gain, defined across various trials as weight gain of $7%, $10%,
or .10% from baseline to end point.
We also coded events that were reported in the categories of
pain, psychiatric events, nausea, and infection. However, because
no sign of elevated risk was gleaned from these data, these analyses
are not reported (data available from authors on request).

The criterion used to establish a minimum level of occurrence for
adverse events reporting in the trial (e.g., if only those adverse
events occurring in at least 5% of participants were reported in the
associated journal article, the adverse events reporting threshold
was coded as 5%). (11) Extent to which the random-sequence
generation procedures were adequate versus inadequate or
unclear [21]. Adequate sequence generation procedures included
use of a computer program, random number table, coin tossing,
randomly drawing envelopes, throwing dice, or similar methods.
Merely describing the trial as randomized was considered an
unclear method of sequence generation. (12) Whether or not the
study eliminated placebo responders prior to randomization. (13)
Whether or not persons who had a prior nonresponse to the study
drug were excluded. (14) Whether or not the placebo was
described as identical to the study drug in terms of at least two of
the following three criteria: taste, appearance, and smell [22]. (15)
Use of blinded raters, coded as affirmative if the following two
conditions were met: (a) it was explicitly stated that blinded raters
were used, and (b) it was explicitly stated that different personnel
were used to rate efficacy measures and adverse events [23–25].
(16) Funding sponsor.
Efficacy and safety outcome data were independently extracted
by two authors (G. I. S. and A. P.) and then checked for
agreement. Disagreements were resolved by checking the original
data source.

Statistical Analysis
The quality of data reporting varied across studies. For
continuous outcomes, effect sizes were computed from means
and standard deviations when possible. When these were not
provided, effect sizes were computed based on means and p-values,
or p-values only. In some studies, three or more treatment groups
were compared, thereby creating a structural dependency that
could affect our estimates. For example, two fixed doses (A and B)
of an adjunctive atypical antipsychotic medication might be
compared to one group that received adjunctive placebo (C), in
which case the estimated efficacy of A and B would be defined
relative to the same comparison group. To maintain independence, we pooled these comparisons and utilized their average
(e.g., the average of A versus C and B versus C).
Each effect size was weighted by its inverse variance in order to
provide a pooled effect size estimate that most accurately
approached the true population effect size [33]. We calculated
odds ratios (ORs) for categorical measures and used Cohen’s d for
continuous measures. We converted continuous effect sizes to
Hedges’g, which corrects for a small bias in Cohen’s d [33]. We
reported both efficacy and safety data for each drug individually
and across drugs. An OR presents a relative measure of treatment
effect; to also provide a measure of absolute benefit/harm, we
calculated the number needed to treat (NNT) for treatment
benefits and the number needed to harm (NNH) for adverse events
[34]. The NNT represents the number of participants who would
need to be treated with an adjunctive antipsychotic to gain one
additional beneficial response over what would have been
obtained had all patients received adjunctive placebo. NNH
represents the number of patients who would require treatment to
generate one additional adverse event relative to placebo. NNT/
NNH values were calculated based on the pooled OR rather than
from the risk difference in each study, as the risk difference is
associated with more between-study heterogeneity than the OR
[35]. Conversions from OR to NNT were performed in Visual Rx
software [36]. The baseline risk (required for calculating NNT)
was estimated by using the pooled rate of events occurring among
placebo-treated patients weighted by each study’s total sample
size. The baseline risk was calculated separately for each drug, so
that placebo participants in one drug’s trials were not used to
calculate baseline risk for a different drug. As in any meta-analysis,
our estimates of NNT and NNH generalize only to situations in

Outcome Measures
Remission was defined variably across studies. We recorded the
most stringent definition of remission utilized in each trial while
also recognizing that the Montgomery–Asberg Depression Rating
Scale (MADRS) [23] was the most commonly used outcome
measure in the included trials. One end-point remission measure
was selected from each trial according to the following order of
priority: MADRS #8, then Hamilton Depression Rating Scale
(HAM-D) #7 [24], then MADRS #10. Some trials of OFC
defined remission as MADRS #8 at two consecutive visits during
the study even if these two consecutive visits did not necessarily
occur at study end point [25–27]. The clinical trial registry reports
of these trials also provided the number of participants who met
remission criteria at an interim time point but then relapsed. For
these studies, we calculated the number of participants in
remission as the number of participants who achieved interim
remission minus the number of patients who subsequently
relapsed.
Response was defined across studies as a 50% improvement
from baseline to end point on either the MADRS or HAM-D [28].
When studies provided response rates for both measures, we used
the MADRS as the response measure, as it was the most
commonly reported measure of response.
We recorded data from any continuous measure of depression,
quality of life, or functioning but opted not to analyze single rating
scale items from larger scales (e.g., individual MADRS items)
separately because they were infrequently reported. When data
were reported on both the MADRS and HAM-D, we included
data from the MADRS, as it was the most commonly used
measure of depressive symptoms. The only continuous self-report
measure of depression used in these trials was the Inventory of
Depressive Symptomatology Self Report [29]. Continuous measures of quality of life included the Quality of Life Enjoyment and
Satisfaction Questionnaire (Q-LES-Q) [30] and the Short Form 36
Health Survey (SF-36) [31]. The only continuous measure of
functional impairment employed in these trials was the Sheehan
Disability Scale (SDS) [32]. As measures of quality of life and
functional impairment varied across studies, we pooled such
PLOS Medicine | www.plosmedicine.org
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The evidence search flow is described in Figure 1. We obtained
one controlled trial of aripiprazole that used low doses (2 or 5 mg);
we did not include this trial because the starting dose of 2 mg was
administered for 30 d prior to participants switching to the dose of
5 mg that falls within the recommended 5–10 mg range set by the
FDA [42]. Characteristics of the 14 included studies are provided
in Table 1. The definition of treatment-resistant depression
differed somewhat across trials. The process by which diagnoses
were made was described clearly in six trials, and the number of
prior failed trials varied across studies. Only three studies clearly
described their random-sequence generation procedures, and only
one trial clearly described using clinical raters who were blind to
both treatment assignment and participants’ reports of adverse
events. While most trials used rating scales to assess for EPS and
akathisia, and a minority of trials used a measure of sexual
functioning, no trial reported using a structured instrument for
eliciting a broad range of adverse events. All studies were funded
by the study drug manufacturer except for one trial that was
funded jointly by the study drug manufacturer and the US
National Institute of Mental Health [27].

participants who achieved remission during treatment, participants assigned to OFC were less likely to remain in remission than
participants assigned to placebo. Only two of 56 placebo
participants relapsed, compared to 18 relapses among 99
participants on OFC (OR, 0.27; 95% CI, 0.08–0.90).
Pooled effect sizes for continuous outcomes are provided in
Table 3. Adjunctive aripiprazole, quetiapine, OFC, and risperidone were all more efficacious than adjunctive placebo based on
clinician-rated measures of depression severity (MADRS/HAMD). Effect sizes were as follows: aripiprazole: g = 0.35 (95% CI,
0.23–0.48); OFC: g = 0.26 (95% CI, 0.04–0.45); quetiapine:
g = 0.40 (95% CI, 0.26–0.53); and risperidone: g = 0.48 (95% CI,
0.22–0.73). The effects of risperidone may have been exaggerated
by the reliance on post hoc analysis rather than a priori analysis in
the largest study of the drug, as the effect of the drug was greater at
6 wk (g = 0.46) than at the prespecified primary end point of 4 wk
(g = 0.32) [44]. According to convention, these effect sizes would be
considered ‘‘small’’ or ‘‘small to moderate’’ in magnitude [45].
Effect sizes on depression severity measures did not differ
significantly between drugs (QB = 1.93, p = 0.59), though there
was limited power to detect such differences. The pooled
difference in mean change on the MADRS in the 11 trials that
reported such data was 2.69. In these 11 trials, the mean effect size
was g = 0.31, which differed only slightly from the overall mean
effect size when including both the HAM-D and MADRS; thus,
the 11 trials reporting MADRS mean change data seem
representative of the entire sample of included trials. Only the
trials of adjunctive aripiprazole reported self-reported depression
symptom severity, yielding a very small effect size of g = 0.15. The
effects observed on the Clinical Global Impressions–Severity Scale
were either small or small-to-moderate, with the exception of
risperidone, for which a moderate effect was generated.
With regards to quality of life and functioning, adjunctive
quetiapine, aripiprazole, and OFC produced effect sizes that were
either not statistically significant or small and clinically negligible
in magnitude. Adjunctive risperidone was more efficacious than
adjunctive placebo on quality of life/functioning, with a small-tomoderate effect size. The pooled effect across quality of life/
functioning measures varied significantly across treatments
(QB = 6.88, p = 0.003), with risperidone (g = 0.49) yielding a higher
effect than the other three drugs combined (g = 0.11), which did
not differ significantly from each other (QB = 4.02, p = 0.13).
However, the effect of aripiprazole on quality of life/functioning
was small (g = 0.22) and statistically significant (p = 0.001), whereas
the effects of OFC (g = 0.04, p = 0.74), and quetiapine (g = 0.05,
p = 0.53) were both not statistically significant and of quite small
magnitude. The effect of aripiprazole on quality of life/functioning
should be interpreted with caution, as the effect for the drug on the
SDS was very small and no longer statistically significant when
patients who violated study protocol were excluded from analysis
(g = 0.12, p = 0.08). Similarly, the effect of risperidone on quality of
life/functioning should be interpreted tentatively since it is largely
driven by post hoc analyses.

Efficacy

Adverse Events

In terms of remission, adjunctive treatment with each antipsychotic was associated with a statistically significant benefit, with
ORs ranging from 1.42 to 2.37 (Table 2). ORs for response were
also statistically significant for aripiprazole, quetiapine, and
risperidone—but not for OFC (Table 2). The NNT for remission
was nine for aripiprazole, quetiapine, and risperidone but was a
substantially higher 19 for OFC (Table 2). NNTs for response
were seven (aripiprazole), eight (risperidone), and ten (quetiapine).
Pooled ORs are displayed visually in Figures 2 and 3 [43]. Among

Atypical antipsychotic medications differed substantially in their
reported adverse event profiles. Table 2 reports adverse events that
showed increased risk (p#0.10). A more detailed listing of adverse
events and pooled ORs for each event category are provided in
Table 4.
Adjunctive aripiprazole was frequently associated with akathisia
(NNH, 4; 95% CI, 3–6) and also linked to a statistically significant
elevation in the occurrence of sedation (NNH, 14; 95% CI, 8–33)
and significant weight gain of $7% during trials (NNH, 29; 95%

which patients receive a similar dosage for a similar treatment
duration; further, estimated NNH and NNT apply only when
generalizing to patients similar to those in the included trials.
Because of various study inclusion and exclusion criteria, patients
in the placebo groups in our meta-analysis may not be
representative of patients seen in some clinical practice settings.
We performed homogeneity analyses using the Q statistic.
Because the Q test of homogeneity often lacks power to detect
heterogeneity when the number of trials in a meta-analysis is small,
we also calculated the I2 statistic [37]. To pool estimates across
studies while incorporating potential heterogeneity, we employed a
random effects model in all analyses [38]. Confidence intervals for
I2 were calculated using Method III as described in Higgins and
Thompson [39] using a spreadsheet. When performing such
calculations in pooled analyses based on only two comparisons
when Q#k, we added the number 1 to both Q and k in order to
avoid the mathematical problem of dividing by zero; this generally
resulted in a slight shrinking of the confidence intervals under
these conditions. Unless specified otherwise above, all analyses
were performed using Comprehensive Meta-Analysis software
[40]. We lacked adequate statistical power to perform subgroup
analyses.
We examined the potential existence of publication bias by
performing trim and fill analysis for pooled continuous depression
outcomes. Trim and fill procedures examine potential asymmetry
of effect sizes. Based on the assumption that effects are distributed
symmetrically, trim and fill analysis imputes the number and likely
effect size of missing studies, then recalculates the pooled analysis
with imputed data from missing studies [41].

Results
Study Characteristics

PLOS Medicine | www.plosmedicine.org
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Figure 1. Flowchart of published studies examined for inclusion in meta-analysis. MDD, major depressive disorder; RCT, randomized
controlled trial.
doi:10.1371/journal.pmed.1001403.g001

The thresholds for adverse event reporting in the included
publications are shown in Table 1. Adverse events were typically
listed in a table and were reported only if a certain proportion of study
participants reported that event. For example, if only those adverse
events reported by 5% or more of participants in either group were
reported in the published journal article, we describe it in Table 1 as
‘‘$5% in any group.’’ In general, little to no additional information
was provided in the study publications regarding adverse events
beyond that which was presented in such tables. Meta-analysis of
effects on sexual functioning rating scales was not performed because
of the often unclear reporting of these measures (see Table 3).

CI, 10–119). Adjunctive OFC was often associated with significant
weight gain of .10% or $10% (NNH, 9; 95% CI, 5–20), sedation
(NNH, 5; 95% CI, 3–12), abnormal metabolic laboratory results
(NNH, 10; 95% CI, 5–29), and elevated prolactin (NNH, 6; 95%
CI, 4–11). Adjunctive quetiapine had a very high rate of reported
sedation (NNH, 3; 95% CI, 2–3) and was also linked to abnormal
metabolic laboratory results (NNH, 6; 95% CI, 4–9) and
significant weight gain of $7% (NNH 37; 95% CI, 12–594).
Adjunctive risperidone was not associated with an increased rate of
any spontaneously reported adverse events.
All four drugs resulted in statistically significant weight gain
(Table 3): mean weight gain in trials of adjunctive aripiprazole,
quetiapine, and risperidone was approximately 1 kg, while the
average weight gain resulting from adjunctive OFC was 4.20 kg
(95% CI, 3.79–4.61). OFC was associated with more weight gain
than the other drugs (QB = 58.46, p,0.001), which did not differ
significantly from each other (QB = 0.66, p = 0.72).
PLOS Medicine | www.plosmedicine.org

Publication Bias
The trim and fill procedure suggested the existence of three
unpublished trials, bringing the overall effect on depression
measures to 0.32. A funnel plot showing the results of this analysis
can be seen in Figure 4.
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$2% in

?

functioning

Remission:

MADRS

response:

6

4

sexual

response:

2 mg permitted

73.5

56.7

any group

HAM-D # 7;

46.1

45.2

.5% in
EPS,

OFC group

EPS

Akathisia,

CTR, FDA

$10% in

Akathisia,

any group

MADRS #8;

M = ?, 1 or

268

95

MADRS

Remission:

response:

mg/fluoxetine

M = 11.0 mg

Aripiprazole

MINI

relapsed;

olanzapine 12

1 historical

patients who

25 mg, or

50 mg

excluding

12 mg/fluoxetine

(2008) [76]

Marcus

(2007) [44]

Various

6

MADRS #8

Remission:

CTR

functioning

response:
MADRS

EPS, sexual

MADRS #8;

Remission:

MADRS
$5% in

functioning

response:

Akathisia,

any group

CTR

$5% in

EPS, sexual

50 mg, olanzapine

Flexible,

Risperidone

72.5

?

any group

functioning

.5% in

sexual

Threshold

Reporting

Events

Akathisia, EPS,

Systematically

Assessed

Adverse

Akathisia,

CTR, FDA

CTR, FDA

Data Sources

d

Supplemental

Events

Adverse

MADRS #10;

Remission:

visits

1 prospective

1 historical,

1 prospective

1–3 historical, ?

1 prospective

1–3 historical, ?

consecutive

45.5

12

6

6

MADRS

6 mg/fluoxetine

432

72.5

73.1

62.8

Remission:

at two

Mahmoud

Various

Various

45.7

45.3

45.4

MINI

25 mg, olanzapine

M = 1.6 mg

Risperidone

Quetiapine

344

343

353

1 historical

Measures

6 mg/fluoxetine

olanzapine

(2009) [73]

Keitner

(2010) [83]

El-Khalili

venlafaxine

Fluoxetine or

Fixed;

OFC

Corya

(2006) [25]

M = 10.7 mg

Flexible,

Various

(2009) [82]

Aripiprazole

Flexible,

Berman

Various
M = 11.8 mg

Aripiprazole

6

Diagnosis

response:

67.6

Trials

c

Depression

b

to Establish

300 mg

45.4

(Weeks)

Duration Failed

Categorical

Interview

MADRS #8;

487

Female

Percent

Prior

150 or

Fixed,

(2007) [75]

Berman

Various

Quetiapine

(2009) [81]

Bauer

(Years)

pressant

Antipsychotic

[Reference]

End Point

Age

Dosage at

Antide-

(Year)

N

a

Mean

Daily

Author

First

Study

Table 1. Characteristics of included studies.

Nonresponders

Placebo

?

?

Yes

?

Yes

?

?

Yes

?

No

Yes

No

No

No

No

Yes

Yes

No

No

Yes

No

No

No

No

Yes

Yes

Yes

Excluded?

Prior Drug

Established

Generation? Resistance?

Sequence

Adequate

?

?

?

?

Yes

?

?

?

?

Similarity?

Placebo

?

?

?

Mostlye

?

?

?

?

?

Raters?

Blinded
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OFC

OFC

OFC

Fluoxetine

Fluoxetine

nortriptyline

Fluoxetine or

?

69.4

8

203

44.1

60.2

8

198

44.9

68.0

8

MADRS

fluoxetine 50 mg

olanzapine 18 mg/

50 mg, or

response:

MADRS #10;

Remission:

12 mg/fluoxetine

prospective

50 mg, olanzapine

6 mg/fluoxetine

Fixed; olanzapine

fluoxetine 50 mg

olanzapine 18 mg/

1 historical, 1 SCID

MADRS

50 mg, or

response:

MADRS #10;

Remission:

12 mg/fluoxetine

prospective

MADRS

response:

relapsed;

50 mg, olanzapine

6 mg/fluoxetine

1 historical, 1 SCID

visits excluding

Fixed; olanzapine

consecutive

35.6 mg
patients who

two

MADRS #8 at

prospective

8.5 mg/fluoxetine

Remission:

1 historical, 1 SCID

MADRS

response:

relapsed;

dose = olanzapine

modal

Flexible, mean

CTR

Akathisia, EPS

CTR

CTR

Akathisia, EPS

Akathisia, EPS

?

group

$10% of OFC ?

group

$10% of OFC ?

group

$10% of OFC ?

reported

visits excluding

52 mg
patients who

events not

consecutive

adverse

Number of

two

42.0

scale), EPS
Akathisia, EPS

participants

Placebo

Established

No

No

No

No

No

Generation? Resistance?

Sequence

Adequate

$13% of total?

Threshold

13.5 mg/fluoxetine

356

CTR

from EPS

Remission:

(one item

Akathisia

Systematically

response: N/A

None

Data Sourcesd

N/A;

Remission:

prospective

2 historical

1 prospective ?

Measuresc

dose = olanzapine

8

8

Diagnosisb

MADRS #8 at

75

69.6

Trials

and 1

42.0

44.0

(Weeks)

modal

20

23

Female

Reporting

Events

Adverse

c

b

Number of participants included in the intent-to-treat or modified intent-to-treat analysis on the primary depression rating scale in the trial.
If no interview was explicitly mentioned, then this variable was coded as ‘‘?’’; MINI, Mini International Psychiatric Interview; SCID, Structured Clinical Interview for DSM-IV.
Indicates measures used to define remission and/or response in each study.
d
‘‘CTR’’ indicates a clinical trial registry report from the sponsor’s online database; ‘‘FDA’’ indicates an FDA statistical review.
e
Blinded raters rated outcomes on the MADRS and HAM-D, whereas the study psychiatrist, who also elicited reports of adverse events, rated the Clinical Global Impressions–Severity.
f
Adverse events reported by fewer than two of the 29 patients in each group were categorized as ‘‘other’’ in the study’s table.
g
Data for these two trials were reported separately for some variables but jointly for others.
M, mean.
doi:10.1371/journal.pmed.1001403.t001

a

(2007) [85]g

Thase 2

(2007) [85]g

Thase 1

(2005) [26]

Shelton

(2001) [27]

Flexible, mean

Fluoxetine

Shelton

OFC

M = 1.17 mg

Flexible,

(2008) [77]

Various

(Years)

Assessed

Risperidone

Na

Depression

Reeves

End Point

to Establish

pressant

Duration Failed

Antipsychotic

Percent

[Reference]

Age

Dosage at

Antide-

(Year)

Categorical
Events

Interview

Adverse
Prior

Author
Mean

Daily

First

Study

Table 1. Cont.
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No

No

No
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?
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?

?
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?
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?

Raters?
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Table 2. Summary of dichotomous efficacy and safety measures.

k

OR (95% CI)a

Q

I2 (95% CI)

p(Q)

Comparison

Outcome

All combined

Remission

13

1.77 (1.49–2.09)

9.20

0% (0%–43.38%)

0.69

10 (8–15)

Response

13

1.61 (1.33–1.95)

19.29

37.78% (0%–67.76%)

0.08

9 (7–16)

Remission

3

2.01 (1.48–2.73)

0.34

0% (0%–38.81%)

0.84

9 (6–18)

Response

3

2.07 (1.58–2.72)

1.60

0% (0%–87.0%)

0.45

7 (5–12)

Akathisia

3

7.47 (5.07–11.0)

1.63

0% (0%–87.24%)

0.44

4 (3–6)

Sedation

3

2.56 (1.63–4.03)

0.68

0% (0%–69.41%)

0.71

14 (8–33)

Weight gain $7%

3

5.91 (2.14–16.29)

0.57

0% (0%–63.50%)

0.75

29 (10–119)

Remission

5

1.42 (1.01–2.0)

4.72

15.19% (0%–82.38%)

0.32

19 (9–713)

Response

5

1.30 (0.87–1.93)

8.13

50.78% (0%–81.95%)

0.09

17 (NNH 34; NNT 7)b

Weight gain $10%

4

16.28 (7.02–37.76)

0.88

0% (0%–47.80%)

0.83

9 (5–20)

Elevated metabolic
lab results

4

4.46 (2.07–9.58)

4.50

33.38% (0%–76.44%)

0.21

10 (5–29)

Sedationc

3

2.87 (1.64–5.03)

7.83

74.45% (0%–92.32%)

0.02

5 (3–12)

Edemad

3

13.19 (5.46–31.89)

0.24

0% (0%–13.32%)

0.89

7 (4–16)

Elevated prolactin

4

4.30 (2.36–7.83)

4.91

38.84% (0%–79.16%)

0.18

6 (4–11)

Aripiprazole

OFC

Quetiapine

Risperidone

NNT/NNH (95% CI)

Akathisia

4

1.48 (0.96–2.30)

3.17

5.36% (0%–85.51%)

0.37

28 (NNH 11; NNT 321)b

Remission

3

1.79 (1.33–2.42)

0.42

0% (0%–50.47%)

0.81

9 (6–19)

Response

3

1.53 (1.17–2.0)

0.79

0% (0%–73.67%)

0.67

10 (6–26)

Sedation

3

8.36 (5.83–11.98)

1.73

0% (0%–87.98%)

0.42

3 (2–3)

Elevated metabolic
lab results

2

2.45 (1.80–3.34)

0.40

0% (0%–85.14%)

0.53

6 (4–9)

Weight gain $7%

3

2.86 (1.11–7.37)

0.97

0% (0%–78.55%)

0.62

37 (12–594)

Remission

2

2.37 (1.31–4.30)

0.01

0% (0%–79.40%)

0.92

9 (5–35)

Response

2

1.83 (1.16–2.88)

0.54

0% (0%–86.49%)

0.46

8 (5–33)

Measures of response and remission are reported for each treatment. Adverse events measures are reported for events that reached a statistical threshold of p,0.10 in
terms of OR. For further description of the data underlying the adverse events effect sizes, see Table 4.
a
Trials with no events in either study arm are not included in summary OR calculations.
b
The 95% confidence interval included the possibility of both treatment-related benefit and treatment-related harm.
c
Because the total number of events in the OFC group was higher than the sample size of the group in Shelton et al [27], an effect size could not be calculated, and it
was thus not factored into the overall effect size estimate for sedation. Given the very small sample of the study, this makes virtually no difference in the overall effect
size estimate.
d
The four trials in which edema was reported for OFC participants had an average rate of 18.32%. Edema was not listed as an adverse event in Shelton et al [26] for any
participants in either the OFC or placebo group. As these data did not fit with the other OFC trials, we excluded this study from the calculation of the risk for placebo
participants.
doi:10.1371/journal.pmed.1001403.t002

evidence was cited for this cutoff [47]. However, Turner et al.’s
meta-analysis of antidepressants versus placebo found an effect size
of 0.31 [11], which was interpreted as ‘‘measurable and
significant’’ [48]. These differing interpretations are understandable given that Cohen noted that his original categorization of
effect sizes (0.2 = small, 0.5 = medium, and 0.8 = large) was
arbitrary [45]. We interpret the effect of adjunctive antipsychotic
treatment on depression measures as of questionable clinical
relevance. In addition, sole reliance on depression rating scales to
determine treatment benefit is likely inadequate in understanding
overall treatment efficacy.
The pooled difference in mean change across 11 trials was 2.69
points on the MADRS. The MADRS consists of ten items, each
rated on a 0–6 scale, assessing sadness, inner tension, reduced
sleep, loss of appetite, concentration, difficulty with starting daily
activities, inability to feel, pessimism, and suicidal thoughts. A
small difference favoring an atypical antipsychotic over placebo on
the MADRS may thus reflect small differences across several
dimensions, or perhaps a sizable difference on one or two
dimensions combined with nil differences on other items. For
instance, a pooled analysis of the two large quetiapine trials

Discussion
In this meta-analysis of 14 randomized trials of atypical
antipsychotic medications used for the adjunctive treatment of
major depressive disorder, we found that all included atypical
antipsychotics were more efficacious than adjunctive placebo in
terms of their effects on depressive symptom severity and
remission. However, the effect sizes were small or small-tomoderate in magnitude, and OFC did not generate a statistically
significant benefit on treatment response. All of the studied drugs
except risperidone demonstrated substantial risk of several adverse
events. Our findings have clinically important implications for
comprehensively understanding the risk–benefit profiles of these
adjunctive treatments for major depressive disorder.
The overall effect size on depression severity was g = 0.34, an
effect conventionally deemed as small. In a meta-analysis of
antidepressants versus placebo, Kirsch et al. found an effect size of
0.32, which they interpreted as not clinically relevant [46]. This
was in line with the recommendations of the National Institute for
Health and Clinical Excellence in the United Kingdom, which
deemed effect sizes of g,0.5 as clinically insignificant, though no
PLOS Medicine | www.plosmedicine.org
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Figure 2. Remission rates by drug and overall.
doi:10.1371/journal.pmed.1001403.g002

version of the study emphasizes outcomes at the end of the 6-wk
trial [44]. However, in its discussion section and the trial’s
associated ClinicalTrials.gov registry entry [52], it is mentioned
that the primary study end point was actually 4 wk; this is
mentioned neither in the paper’s methods section nor in the
abstract. The effect size on the HAM-D is 30% smaller at the 4-wk
end point relative to the 6-wk end point. Effects on the Q-LES-Q
and SDS were reported only at week 6, but it seems likely that
these effects would be smaller at the primary study end point.
Given that this study included 69% of the total participants in
risperidone trials, our pooled estimate of risperidone efficacy is
therefore driven by the inclusion of post hoc analyses. Further, a
previously published relapse prevention study (not included in our
meta-analysis due to its study design) found no benefit for
risperidone over placebo, suggesting that risperidone-related gains
may be transient [53,54].
Taken together, our findings raise significant concerns regarding the impact of these medications in improving overall well-being.
Although improvements in quality of life or functional status
commonly co-occur with improvements in depression symptom
severity, this cannot automatically be assumed. One comprehensive literature review estimated only a moderate degree of
correlation between these constructs [55]. It has been argued that
changes on quality of life measures may lag changes on depressive
symptom measures and that short-term trials may not be an
appropriate setting in which to estimate changes on quality of life
measures [15]. Contrary to this argument, however, four of five
recently published short-term antidepressant medication trials

included in our meta-analysis found that quetiapine at 150 mg/d
and quetiapine at 300 mg/d were superior to placebo by 2.50 and
2.85 points on the MADRS at study end point, respectively [49].
The treatment advantage in terms of the items ‘‘apparent sadness’’
and ‘‘reported sadness’’ appears to be about a third of that for the
‘‘reduced sleep’’ item (Figure 3b of [49]), suggesting that
quetiapine’s sedative effect on sleep may account for a substantial
degree of the observed improvement in depression scores. Thus,
improvement in overall depression rating scales should be
interpreted cautiously.
Response and remission rates are often used to convey the
magnitude of treatment benefit; however, these categorical
measures are created arbitrarily from underlying continuous
rating scale data [50]. In some circumstances these categorical
measures may inflate treatment differences relative to mean
change on the continuous scale [51]. While response and
remission rates are potentially useful outcome measures, they
should be considered only in the context of a wider set of outcome
data.
With the exception of risperidone, nearly all of the included
trials estimated small or minimal benefits with regards to quality of
life and functional impairment. Quetiapine and OFC generated
no benefit on such measures, whereas the benefits of aripiprazole
were statistically significant yet quite modest. Although risperidone
appeared to possess the strongest risk–benefit profile in our
analyses, our findings about risperidone were based on the smallest
sample size of any of the included drugs. We also have concerns
about data reported in the largest risperidone trial. The published
PLOS Medicine | www.plosmedicine.org
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Figure 3. Response rates by drug and overall.
doi:10.1371/journal.pmed.1001403.g003

found that benefits of medication over placebo were similar on
measures of (1) quality of life or functional impairment (e.g., as
measured by the Q-LES-Q and SDS) and (2) depression symptom
severity (e.g., as measured by the HAM-D and MADRS) [56–60].
Our findings highlight the fact that reporting data only on
symptom response and resolution may provide an incomplete and
perhaps overly optimistic summary of a medication’s overall effects
on well-being [15,16,61]. More robust assessments of quality of life
and functional impairment should be incorporated into the design
of clinical trials of any putative antidepressant.
Without longer-term data on not only depression symptom
severity but also quality of life and social functioning, it is difficult
to assess the risk–benefit profile of these medications prescribed
over the long term. None of the included trials provided data on
long-term (i.e., $6 mo) outcomes comparing adjunctive antipsychotic medication treatment to adjunctive placebo. Our failure to
find long-term outcome data is consistent with that of previous
research teams [17,62]. For example, one systematic review of
long-term, two-arm parallel randomized controlled antidepressant
trials initially identified 2,693 abstracts, only to ultimately include
six trials [62]. This limitation is shared with other treatments; there
is very little understanding of how adjunctive treatments for
depression influence long-term well-being.
In addition to providing a thorough assessment of efficacy
outcomes, our meta-analysis departs from the literature in a
second notable way by comprehensively summarizing the available safety information on these medications. Such safety data
PLOS Medicine | www.plosmedicine.org

have not been included in prior quantitative reviews, but our
conclusions echo concerns raised in previous meta-analyses and a
narrative review regarding potential treatment-related harms
associated with use of atypical antipsychotic medication in the
adjunctive treatment of depression [6–8]. Overall, we found that
treatment was linked to several adverse events, including akathisia
(aripiprazole), sedation (quetiapine, OFC, and aripiprazole),
abnormal metabolic laboratory results (quetiapine and OFC),
and weight gain (all four drugs, especially OFC). Measures of
absolute benefit and harm (NNT and NNH) provide an intuitive
metric for understanding treatment-related benefits and harms.
However, these measures are dependent on baseline control group
risk, which may vary substantially across clinical subgroups [63].
Thus, our findings in terms of NNT and NNH should be
interpreted as estimates of effects for each drug relative to control
participants who may differ from participants treated in clinical
practice.
Our ability to provide an adequate safety profile of these
medications was limited in two respects. First, while 11 of 14
included trials used a structured instrument to elicit adverse events,
these measures were limited to assessing potential EPS- and
akathisia-related events, and, in five studies, sexual functioning. No
study reported using a structured checklist to elicit adverse events
outside of EPS, akathisia, or sexual functioning, which is a
substantial limitation given that adverse events are reported with
as much as 20 times greater frequency when elicited through
structured checklists versus being recorded in response to patient
10
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OFC

Depression

Aripiprazole

11
MADRS

SFI overall satisfaction

Sexual functioning

Depression

Weight gain (kg)

CGI-S

Q-LES-Q

SDS

IDS-SR

MADRS

Outcome

Metabolic parameters

Global improvement

QoL/functioning

Outcome Type

Drug

0.38 (0.26, 0.50)

Total

1.04
0.08
0.14

Shelton (2005) [26]
Thase 1 (2007) [85]

?b

Total

0.15

?

Shelton (2001) [27]

0.25

Marcus (2008) [76]

Corya (2006) [25]

?

1.40

0.65

12.40

1.35

Total

Berman (2009) [82]

1.05 (0.35, 1.74)

Marcus (2008) [76]

Berman (2007) [75]

0.4
1.05

Berman (2009) [82]

1.67

0.46

Berman (2007) [75]

0.31

Marcus (2008) [76]

0.23 (0.11, 0.36)
0.22 (0.09, 0.34)

Total QoL/functioning
0.37

0.28

Total

Berman (2009) [82]

0.26

Marcus (2008) [76]

Berman (2007) [75]

0.16

0.20 (0.08, 0.33) (0.12
[20.02, 0.26])a

Berman (2009) [82]

0.25 (0.10)a

Total
Berman (2007) [75]

0.16

Marcus (2008) [76]

0.15 (0.03, 0.27)

Berman (2009) [82]

0.14

Total
0.19 (0.10)a

0.13

Marcus (2008) [76]

Berman (2007) [75]

0.17

0.35 (0.23, 0.48) (0.33
[0.20, 0.47])a

Total

Berman (2009) [82]

0.32 (0.26)a

Marcus (2008) [76]

Berman (2007) [75]

0.38

3.15 (2.07, 4.23)
(3.14 [1.87, 4.41])a

3.73
2.84 (2.52)

0.35 (0.33)

3.01 (3.01)

Raw Units (95% CI
for Totals)

Berman (2009) [82]

a

g+ (95% CI
for Totals)

Berman (2007) [75]

Study First Author
(Year) [Reference]

Table 3. Effect sizes and heterogeneity of effect sizes on continuous measures.

0.003

,0.001

0.001

,0.001

0.001 (0.08)a

0.02

,0.001 (,0.001)a

p(g+)

12.03

1.05

0.33

0.64

0.37 (0.17)a

0.08

0.18 (0.53)a

Q

83.38% (49.64%–
94.51%)

0% (0%–80.19%)

0% (0%–36.96%)

0% (0%–67.50%)

0% (0%–43.78%)
(0% [0%–0%])a

0% (0%–0%)

0% (0%–0%) (0%
[0%–60.75%])a

I2 (95% CI)

0.002

0.59

0.85

0.73

0.83 (0.92)a

0.96

0.92 (0.77)a

p(Q)
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Weight gain (kg)

Metabolic parameters

Cholesterol (total
nonfasting, mg/dl)

Prolactin (ng/ml)

CGI-S

Prolactin

Global improvement

SF-36 MCS

QoL

SF-36 PCS

Outcome

Outcome Type

Table 3. Cont.

7.59

4.20 (3.79, 4.61)
0.28

Total
Corya (2006) [25]

3.88
4.5

Thase (2007) [85]

5.79

Shelton (2005) [26]

Shelton (2001) [27]

2.50
3.98

0.27

Thase (2007) [85]

2.57 (0.33, 4.81)

5.60

Raw Units (95% CI
for Totals)

Corya (2006) [25]

?d

Shelton (2005) [26]

0.20 (0.08, 0.32)

0.08

Thase 1 (2007) [85]
0.32

0.27

Shelton (2005) [26]

Total

0.31

Shelton (2001) [27]

Thase 2 (2007) [85]

0.12

Corya (2006) [25]

0.04 (20.19, 0.26)

Thase (2007) [85]

Total QoL

20.13
0.19

Shelton (2005) [26]

0.03 (20.23, 0.30)

20.06

Shelton (2001) [27]

Total

nsc

0.04 (20.17, 0.25)

Total
Corya (2006) [25]

20.10
0.13

Thase (2007) [85]

0.50

Shelton (2005) [26]

Shelton (2001) [27]

0.26 (0.04, 0.45)

Total
nsc

0.57

Thase 2 (2007) [85]

Corya (2006) [25]

g+ (95% CI
for Totals)

Study First Author
(Year) [Reference]

,0.001

0.001

0.74

0.82

0.72

0.02

p(g+)

3.33

2.35

3.46

4.57

3.13

11.37

Q

0.67

0.18

0.10

0.21

0.02

p(Q)

9.80% (0%–86.21%) 0.34

0% (0%–64.60%)

42.20% (0%–
82.51%)

56.25% (0%–
87.52%)

36.18% (0%–
79.57%)

64.83% (7.70%–
86.59%)

I2 (95% CI)
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Depression

Quetiapine

13
El-Khalili (2010) [83]

(mg/dl)

0.36

0.27

0.19 (0.06, 0.33)

Total
Bauer (2009) [81]

0.18

El-Khalili (2010) [83]

0.11 (20.03, 0.24)

Total

0.21

0.04

El-Khalili (2010) [83]

Bauer (2009) [81]

0.17

20.21
20.16 (20.29, 20.02)

El-Khalili (2010) [83]
Total
Bauer (2009) [81]

20.11

Bauer (2009) [81]

Triglycerides

Total cholesterol (mg/dl)

LDL cholesterol (mg/dl)

HDL cholesterol (mg/dl)

Total

Metabolic parameters

20.08
20.02 (20.16, 0.12)

El-Khalili (2010) [83]

Prolactin (mIU/L)

0.44 (0.26, 0.62)
0.03

Bauer (2009) [81]

Total
Prolactin (ng/ml)

0.69

McIntyre (2007) [84]

Prolactin

?g

El-Khalili (2010) [83]

0.04 (20.09, 0.18)

Total
0.41

20.02

El-Khalili (2010) [83]

Bauer (2009) [81]

0.10

Bauer (2009) [81]

38.09

19.65

5.68 (1.57, 9.79)

4.83

6.51

2.86 (21.03, 6.76)

0.77

4.75

21.38 (22.58, 20.18)

21.82

21.0

212.12

0.44

2.68f

0.40 (0.26, 0.53)f

Total

2.45
5.70

0.34

2.89

23.90 (2.39, 45.41)

23.90

10.85 (4.28, 17.43)

0.71

El-Khalili (2010) [83]

?
14.3

e

Raw Units (95% CI
for Totals)

McIntyre (2007) [84]

0.41

0.22 (0.02, 0.41)

Bauer (2009) [81]

0.22

0.37 (0.21, 0.54)

Total

Total

0.43

Thase (2007) [85]

?

Thase (2007) [85]

e

g+ (95% CI
for Totals)

Shelton (2005) [26]

Study First Author
(Year) [Reference]

CGI-S

Q-LES-Q

HAM-D

MADRS

Triglycerides (mg/dl)

Outcome

Global Improvement

QoL

Outcome Type

Drug

Table 3. Cont.

0.01

0.12

0.02

0.77

,0.001

0.53

,0.001

0.03

,0.001

p(g+)

0.07

0.91

0.43

0.61

0.99

0.68

1.69

N/A

1.25

Q

0% (0–80.47%)

0% (0%–89.11%)

0% (0%–85.45%)

0% (0%–87.08%)

0% (0%–89.55%)

0% (0%–87.62%)

0% (0%–87.69%)

N/A

19.88% (0%–
90.75%)

I2 (95% CI)

0.80

0.34

0.43

0.43

0.32

0.41

0.43

N/A

0.26

p(Q)

Atypical Antipsychotic Augmentation for MDD
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Risperidone

Drug

14
Prolactin (ng/ml)

Weight gain (kg)

Weight gain

CGI-S

SDS

Q-LES-Q
0.43 (0.20, 0.66)l

Total

38.85 (25.67, 83.37)

1.13
20.45
1.26

Mahmoud (2007) [44]
Reeves (2008) [77]
Total

1.81

0.80 (20.19, 1.80)

Total
Keitner (2009) [73]

0.80

Reeves (2008) [77]

Mahmoud (2007) [44]m

Keitner (2009) [73]m

0.64 (0.42, 0.87)

0.72
0.78

Reeves (2008) [77]
Total

0.44

Mahmoud (2007) [44]

,0.001

0.11

,0.001

,0.001

Keitner (2009) [73]

,0.001

0.57 (0.28, 0.85)l
0.49 (0.26, 0.73)l

,0.001

,0.001 (0.004)

Total

38.85

7.11

,0.001

,0.001

p(g+)

Total QoL/functioning

0.57l

0.39l

Mahmoud (2007) [44]

Mahmoud (2007) [44]

0.54

Keitner (2009) [73]

0.60
0.48 (0.22, 0.73) (0.34 [0.11,
0.58])j,k

Reeves
Total

MADRS

2.80 (1.90)j

Mahmoud (2007) [44]

HAM-D

?

Keitner (2009) [73]

nsi

?

Total
0.46 (0.32)j

?h

El-Khalili (2010) [83]

0.94 (0.62, 1.26)

Total
0.01

2.65

McIntyre (2007) [84]

Bauer (2009) [81]

0.95
0.89

26.90 (9.24–44.57)

Bauer (2009) [81]

0.31 (0.17, 0.45)

Total

Raw Units (95% CI
for Totals)

El-Khalili (2010) [83]

g+ (95% CI
for Totals)

Study First Author
(Year) [Reference]

MADRS

CSFQ

Weight gain (kg)

Outcome

Prolactin

Global improvement

QoL/functioning

Depression

Sexual functioning

Outcome Type

Table 3. Cont.

3.51

N/A

1.29

0.05

N/A

0.33

0.09 (0.42)

1.03

0.38

Q

42.95% (0%–
82.87%)

N/A

0% (0%–83.87%)

0% (0%–80.19%)

N/A

0% (0%–84.36%)

0% (0%–80.91%)
(0% [0%–85.35%])

0% (0%–79.80%)

0% (0%–84.93%)

I2 (95% CI)

0.17

N/A

0.53

0.82

N/A

0.56

0.76 (0.52)

0.60

0.54

p(Q)

Atypical Antipsychotic Augmentation for MDD
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Outcome Type

0.17 (0.06, 0.28)

QoL/functioningo

g+ (95% CI
for Totals)
0.34 (0.25, 0.43)

Study First Author
(Year) [Reference]

MADRS/HAM-D

Outcome
2.69 (1.82, 3.54)

n

Raw Units (95% CI
for Totals)

0.003

,0.001

p(g+)

18.25

19.44

Q

50.68% (0%–
76.05%)

38.26% (0%–
67.99%)

I2 (95% CI)

0.03

0.08

p(Q)

a
The FDA statistical review noted that many participants violated study protocol, often as a result of taking non-allowed medications. The numbers in parentheses represent data from only participants who did not violate the
study protocol.
b
As data were not presented clearly for two of three trials, we opted to not treat the single study with clearly reported data as representative of the three aripiprazole studies; thus, we provide no summary effect size calculation for
sexual functioning.
c
‘‘ns’’ indicates no statistically significant difference versus placebo; data were not reported in a more detailed manner.
d
OFC had a greater increase in prolactin versus fluoxetine (0.31 nmol/l, p,0.001) and versus nortriptyline (0.37 nmol/l, p,0.001). Given the inexact p-values, we did not calculate an effect size.
e
OFC had a greater increase in mean total nonfasting cholesterol versus fluoxetine (0.30 mmol/l, p,0.001) and nortriptyline (0.33 mmol/l, p = 0.004). Given the inexact p-value of the OFC versus fluoxetine comparison, we did not
calculate an effect size.
f
Hedges’ g includes effects from all three trials, whereas the raw unit analysis includes only change on the MADRS, which was not used in the McIntyre et al. [84] study.
g
It was reported that 150 mg of quetiapine was superior to placebo, with an associated p-value of 0.095, from which a d = 0.20 was calculated. For the 300-mg dose, the p-value was reported as ,0.05, so it was not possible to
calculate an exact effect size, as a standard deviation for this measure was not provided.
h
There were ‘‘no apparent differences among the treatment groups’’ according to the El-Khalili et al. [83] clinical trial registry report. Given the lack of clarity regarding sexual functioning data, we provide no summary effect size
calculation for sexual functioning.
i
‘‘ns’’ indicates no statistically significant difference versus placebo; data were not reported in a more detailed manner.
j
The primary efficacy end point in the Mahmoud et al. [44] study was 4 wk, so data in parentheses indicate data from this a priori end point rather than from the 6-wk end point that was emphasized much more heavily in the study
publication.
k
Hedges’ g pools data from Mahmoud et al. [44] and Reeves et al. [77]. We provide no summary estimate of mean differences on the MADRS, as only the small Reeves et al. [77] study reported these data.
l
Mahmoud et al.’s primary end point was 4 wk [44], but these data are presented at 6 wk. These results may be inflated relative to the primary end point, given that the effect favoring risperidone on the HAM-D was smaller at week
4 than at week 6.
m
Prolactin levels were apparently not measured in these trials.
n
Pooled raw units are for MADRS only.
o
These data are pooled across the SDS, Q-LES-Q, SF-36 Mental Component Summary, and SF-36 Physical Component Summary.
CGI-S, Clinical Global Impressions–Severity; CSFQ, Changes in Sexual Function Questionnaire; IDS-SR, Inventory of Depressive Symptomatology–Self Report; QoL, quality of life; SF-36 MCS, SF-36 Mental Component Summary; SF-36
PCS, SF-36 Physical Component Summary; SFI, Sexual Function Inventory.
doi:10.1371/journal.pmed.1001403.t003
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Drug
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Table 4. Adverse events individually and by category.

Drug

Study First Author (Year)
[Reference]

Event

Events/N on
Drug

Events/N on
Placebo

Aripiprazole

Berman (2007) [75]

Fatigue

11/182

6/176

Berman (2009) [82]

Fatigue

16/176

8/172

Sedation

10/176

1/172

Fatigue

19/189

7/190

Marcus (2008) [76]

Somnolence

13/189

7/190

Total

Sedation-related

69/547

29/538

Berman (2007) [75]

Tremor

6/182

8/176

Other EPS-related events

2/182

1/176

Dyskinesia

2/176

0/172

Extrapyramidal disorder

2/176

0/172

Muscle spasms

4/176

1/172

Muscle twitching

3/176

3/172

Psychomotor activity

1/176

0/172

Tremor

5/176

6/172

Marcus (2008) [76]

Tremor

12/189

5/190

Total

EPS-related

37/547

24/538

Berman (2007) [75]

Metabolic labsb

?

?

Berman (2009) [82]

Metabolic labsc

?

?

Marcus (2008) [76]

Metabolic labsd

?

?

Total

Metabolic labs

?

?

Berman (2007) [75]

Akathisia

42/182

8/176

Restlessness

26/182

6/176

Berman (2009) [82]

Akathisia

32/176

6/172

Restlessness

22/176

6/172

Marcus (2008) [76]

Akathisia

49/189

8/190

Berman (2009) [82]

OFC

Restlessness

18/189

1/190

Total

Akathisia-related

189/547

35/538

Berman (2007) [75]

Weight gain $7%

13/182

2/176

Berman (2009) [82]

Weight gain $7%

8/176

2/172

Marcus (2008) [76]

Weight gain $7%

6/189

0/190

Total

Weight gain $7%

27/547

4/538

Corya (2006) [25]

Asthenia

29/243

10/119

Somnolence

53/243

8/119

Asthenia

5/10

4/10

Shelton (2001) [27]

Somnolencee

6/10

5/10

Shelton (2005) [26]

Asthenia

30/146

25/210

Somnolence

25/146

27/210

Thase (2007) [85]

Fatigue

28/200

16/206

Hypersomnia

21/200

5/206

Sedation

19/200

7/206

Somnolence

35/200

11/206

Total

Sedation

240/589

109/535

Corya (2006) [25]

Dyskinesia any time (AIMS)

1/227

3/113

Dyskinesia at last two visits (AIMS)

0/227

1/113

Dyskinesia at end point (AIMS)

1/227

1/113

Parkinsonism (SAS)

6/226

7/113

PLOS Medicine | www.plosmedicine.org
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OR (95% CI)a

2.56 (1.63–
4.03)

1.54 (0.86–
2.74)

7.47 (5.07–
11.0)

5.91 (2.14–
16.29)

2.87 (1.64–
5.03)
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Drug

Events/N on
Drug

Events/N on
Placebo

Study First Author (Year)
[Reference]

Event

Shelton (2001) [27]

Parkinsonism (SAS)

0/10

3/9

Shelton (2005) [26]

Dyskinesia any time (AIMS)

2/140

0/197

Dyskinesia at last two visits (AIMS)

0/140

0/197

Dyskinesia at end point (AIMS)

0/140

0/197

Parkinsonism (SAS)

7/140

1/199

Tremor

17/146

8/210

Dyskinesia any time (AIMS)

1/196

3/201

Dyskinesia at last two visits (AIMS)

0/195

0/201

Dyskinesia at end point (AIMS)

0/194

1/199

Parkinsonism (SAS)

5/192

2/195

Tremor

21/200

18/206

Total

EPS-related

61/574

48/522

Corya (2006) [25]

Cholesterol high

12/213

0/103

Nonfasting glucose high

6/209

0/103

HbA1c high

10/153

1/77

Cholesterol high

1/10

0/10

Nonfasting glucose high

0/10

0/10

Cholesterol high

3/133

7/193

Nonfasting glucose high

8/131

3/192

Hyperglycemia

3/146

0/200

Cholesterol high

9/189

3/194

Thase (2007) [85]

Shelton (2001) [27]

Shelton (2005) [26]

Thase (2007) [85]

Fasting glucose high

2/28

0/36

Nonfasting glucose high

6/168

1/170

HbA1c high

8/144

0/165

Triglycerides high

10/189

3/196

Total

Metabolic labsf

78/482

18/455

Corya (2006) [25]

Agitation

14/243

4/119

Akathisia any time (Barnes)

23/227

5/109

Akathisia

2/10

0/10

Akathisia (Barnes)

3/10

2/9

Shelton (2005) [26]

Akathisia (Barnes)

14/138

20/196

Thase (2007) [85]

Akathisia (Barnes)

18/188

13/188

Total

Akathisia

74/571

44/508

Corya (2006) [25]

Prolactin high

43/186

7/89

Shelton (2001) [27]

Prolactin high

4/9

0/7

Shelton (2005) [26]

Prolactin high

34/119

6/178

Thase (2007) [85]

Prolactin high

49/159

23/172

Total

Prolactin highg

130/473

36/446

Corya (2006) [25]

Peripheral edema

27/243

1/119

Edema

19/243

1/119

Shelton (2001) [27]

Peripheral edema

2/10

0/10

Thase (2007) [85]

Peripheral edema

24/200

2/206

Edema

11/200

1/206

Edema

83/453

5/335

Corya (2006) [25]

Weight gain $10%

53/230

2/114

Shelton (2001) [27]

Weight gain $10%

3/10

0/10

Shelton (2001) [27]

Total
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OR (95% CI)a

0.88 (0.25–
3.04)

4.46 (2.07–
9.58)

1.48 (0.96–
2.30)

4.30 (2.36–
7.83)

13.19 (5.46–
31.89)
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Drug

Quetiapine

Event

Events/N on
Drug

Events/N on
Placebo

Shelton (2005) [26]

Weight gain .10%

11/146

0/210

Thase (2007) [85]

Weight gain $10%

42/198

2/203

Total

Weight gain .10% or weight gain $10%

109/584

4/537

Bauer (2009) [81]

Fatigue

46/330

5/161

Lethargy

7/330

2/161

Sedation

37/330

7/161

Study First Author (Year)
[Reference]

Somnolence

66/330

5/161

Fatigue

33/297

7/148

Hypersomnia

6/297

0/148

Sedation

58/297

6/148

Somnolence

86/297

6/148

McIntyre (2007) [84]

Sedation/somnolence/lethargy

25/29

14/29

Total

Sedation-related

364/656

52/338

Bauer (2009) [81]

EPS-related

None

None

El-Khalili (2010) [83]

EPS-related

17/297

5/148

McIntyre (2007) [84]

EPS-related

None

None

Total

EPS-related

17/297

5/148

Bauer (2009) [81]

Fasting glucose high

15/330

4/161

LDL cholesterol high

47/330

18/161

HDL cholesterol low

13/330

7/161

El-Khalili (2010) [83]

El-Khalili (2010) [83]

Total cholesterol high

60/330

14/161

Triglycerides high

40/330

5/161

Fasting glucose high

11/297

5/148

HbA1c high

2/297

1/148

HDL cholesterol low

18/297

7/148

LDL cholesterol high

12/297

5/148

Total cholesterol high

22/297

2/148
6/148

Triglycerides high

29/297

McIntyre (2007) [84]

Metabolic labsh

?

?

Total

Metabolic labsi

269/627

74/309

Bauer (2009) [81]

Shift from ,3 to $3 metabolic risk factors

27/330

16/161

El-Khalili (2010) [83]

Shift from ,3 to $3 metabolic risk factorsj

50/297

9/148

Total

Shift from ,3 to $3 metabolic risk factors

77/627

25/309

El-Khalili (2010) [83]

Akathisia

6/297

1/148

Restlessness

5/297

2/148

Total

Akathisia-related

11/297

3/148

Bauer (2009) [81]

Elevated prolactink

6/330

3/161

Total

Elevated prolactin

6/330

3/161

Bauer (2009) [81]

Weight gain $7%

14/330

2/161

El-Khalili (2010) [83]

Weight gain $7%

13/297

3/148

McIntyre (2007) [84]

Weight gain $7%

4/18

0/14

Total

Weight gain $7%

31/645

5/323
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OR (95% CI)a

16.28 (7.02–
37.76)

8.36 (5.83–
11.98)

1.66 (0.59–
4.67)

2.45 (1.80–
3.34)

1.57 (0.42–
5.92)

1.75 (0.47–
6.55)

0.96 (0.23–
3.96)

2.86 (1.11–
7.37)
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Drug

Study First Author (Year)
[Reference]

Event

Events/N on
Drug

Events/N on
Placebo

Risperidone

Keitner (2009) [73]

Fatigue

0/62

2/33

Tired

0/62

2/33

Fatigue

5/137

0/131

Lethargy

1/137

3/131

Mahmoud (2007) [44]

Somnolence

7/137

2/131

Reeves (2008) [77]

Somnolence

2/12

1/11

Total

Sedation-related

15/211

10/175

Mahmoud (2007) [44]

Dystonia

0/137

1/131

Tremor

1/137

1/131

Total

EPS-related

1/137

2/131

Keitner (2009) [73]

Metabolic labsl

?

?

Mahmoud (2007) [44]

Metabolic labsl

?

?

Reeves (2008) [77]

Metabolic labsl

?

?

Total

Metabolic labs

?

?

Mahmoud (2007) [44]

Akathisia

1/137

0/131

Total

Akathisia-related

1/137

0/131

Keitner (2009) [73]

Edema

0/62

0/33

Mahmoud (2007) [44]

Peripheral edema

4/137

1/131

Reeves (2008) [77]

Edema

0/12

0/11

Total

Edema

4/211

1/175

Keitner (2009) [73]

Weight gain $7%

2/62

0/33

Mahmoud (2007) [44]

Weight gain $7%

m

?

?

Reeves (2008) [77]

Weight gain $7%m

?

?

Total

Weight gain $7%

2/62

0/33

OR (95% CI)a

0.88 (0.11–
7.55)

0.47 (0.04–
5.29)

2.89 (0.12–
71.58)

3.91 (0.43–
35.45)

2.77 (0.13–
59.38)

a

Trials with no events in either study arm are not included in summary OR calculations.
The clinical registry report indicated that statistically significant differences emerged between drug and placebo in glucose, total cholesterol, fasting LDL cholesterol,
nonfasting and fasting triglycerides, and prolactin. These differences were not reported quantitatively and were described as not ‘‘clinically meaningful.’’
c
Median levels of change in fasting total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and fasting plasma glucose were reported. Categorical measures
(i.e., numbers of patients who had abnormal scores) were not reported. The clinical trial registry noted that there was a statistically significant but clinically
nonmeaningful difference between drug and placebo on nonfasting LDL cholesterol.
d
Data on metabolic parameters were reported in terms of median change, but no categorical reporting of laboratory abnormalities was provided. Differences between
drug and placebo were reported as not statistically significant in terms of median change on glucose, cholesterol, and triglycerides.
e
Because the total number of events in the OFC group was higher than the sample size of the group, an effect size could not be calculated, and it was thus not factored
into the overall effect size estimate for sedation. Given the very small sample of the study, this makes virtually no difference in the overall effect size estimate.
f
The number of participants providing data differed substantially across metabolic testing parameters. The average sample size across the metabolic testing groups
provided the denominator for the pooled number of abnormal metabolic test results in each trial, with the total number of participants who experienced an abnormal
metabolic testing result comprising the numerator. A participant may have experienced more than one event. Also, boundaries of abnormal tests were defined by
standard Lilly reference ranges, a resource not available to our research team.
g
Boundaries of abnormal tests were defined by standard Lilly reference ranges, a resource not available to our research team.
h
Triglycerides and unclearly described laboratory tests were completed in this study, but the results were described only as yielding ‘‘no clinically significant differences’’
between groups.
i
Abnormal metabolic laboratory values were defined as follows: fasting glucose $126 mg/dl, LDL cholesterol $160 mg/dl, HDL cholesterol #40 mg/dl, total cholesterol
$240 mg/dl, and triglycerides $200 mg/dl.
j
The clinical trial registry entry noted that approximately 17% of patients taking quetiapine met this criterion, compared to 6% of placebo patients. We extracted
numbers of patients based on these percentages.
k
Defined as .20 ng/ml for males and .30 ng/ml for females.
l
These parameters were apparently not measured.
m
Weight gain was provided in terms of means and standard deviations; however, no categorical measure of significant weight gain was reported.
AIMS, Abnormal Involuntary Movement Scale; Barnes, Barnes Akathisia Scale; HbA1c, glycated hemoglobin; SAS, Simpson-Angus Scale.
doi:10.1371/journal.pmed.1001403.t004
b

complaints [19,20]. The importance of measuring adverse events
systematically was demonstrated historically in the case of selective
serotonin reuptake inhibitors: in registration trials, sexual dys-
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function was neither systematically assessed nor found to be
frequently spontaneously reported by patients [64,65]. Further
investigation indicated, however, that sexual side effects on
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Figure 4. Funnel plot of trim and fill analysis. Open circles represent published studies; filled circles represent imputed unpublished studies.
The overall effect size changes from 0.34 to 0.32 when including these imputed trials.
doi:10.1371/journal.pmed.1001403.g004

of the double-blind in the trials included in our meta-analysis is
consistent with the wider clinical trials literature [72]. The
potential for unblinding to cause inflated efficacy ratings among
clinical raters could be substantially limited if efficacy outcomes
were assessed by different personnel than those who assessed
adverse events [70]. Yet the use of separate raters to assess efficacy
and safety outcomes was reported in only one trial [73].
The FDA statistical reviewer for aripiprazole [74] wrote
regarding Berman et al. [75] that ‘‘the medical reviewer is
concerned about the considerable number of protocol violations
in the study primarily due to usage of opiates/barbiturates’’ [74].
Regarding the Marcus et al. [76] trial, the FDA reviewer wrote that
the difference between groups in the number of participants who
used prohibited medications was ‘‘huge’’ [74], with nine patients in
the placebo group doing so compared to 24 in the aripiprazole
group. The reviewer thus performed a separate analysis, excluding
patients in the two trials who violated the study protocol, the results
of which indicated a minimal, non-statistically significant effect of
aripiprazole on functional status. In the journal articles, this
potentially important issue is not mentioned. The FDA reviewer
reported results only from reanalysis of the MADRS and SDS, so it
is unknown to what extent these protocol violations may have
impacted results on other outcome measures [74].
Our results differ somewhat from those of Nelson and
Papakostas, whose meta-analysis concluded that augmentation with
atypical antipsychotics was effective and, further, that ‘‘this body of
evidence is considerably larger than that for any other augmentation strategy in the treatment of major depressive disorder’’ [6].
There are seven differences in our analyses that provide reasons why
we reached different conclusions. The greatest divergence in our
results was regarding OFC, for which we found a lower OR
favoring OFC for remission (1.42) than did Nelson and Papakostas
(1.83). In this first instance, Nelson and Papakostas utilized whatever
definition of remission was provided by the authors of each study,
whereas we used a more restrictive definition. Three OFC trials
defined remission as achieving a MADRS score of #8 at two
consecutive visits—even if patients relapsed during the trial [25–27].

selective serotonin reuptake inhibitors are actually quite common
[19]. While the collection of adverse event data via structured
checklists is a more sensitive method of collecting adverse event
data, it may result in many common (mostly minor) health
problems being endorsed even if they are not due to treatment,
potentially leading to decreased specificity in differentiating
medications from placebo [66]. To bridge the differences between
the systematic and open-ended assessment of adverse events in
clinical trials, some sort of hybrid method of collecting adverse
event data could be performed, such as randomly assigning some
participants within both the active treatment and placebo groups
to complete a structured checklist while assigning others to
complete an open-ended assessment of adverse events.
A second constraint on our ability to adequately summarize the
drugs’ safety profiles is that many adverse events were not reported in
journal articles and that some of the data were incomplete or reported
in a fashion that may have obscured treatment-related harms. We
agree with the Cochrane reviewers that ‘‘data on side effects were
often very poorly described’’ [9]. Conceptually similar events such as
sedation, fatigue, and somnolence were sometimes reported
separately, often with no attempt to pool them together. This is in
direct contradiction to FDA guidance, which states that events that
‘‘represent the same phenomenon (e.g., somnolence, sedation,
drowsiness) should ordinarily be grouped together as a single adverse
reaction to avoid diluting or obscuring the true effect’’ [67].
Given the notable side effect profiles of the studied drugs, it is
likely that the double-blind was significantly compromised;
however, none of the included trials tested the integrity of
blinding. For example, patients who rapidly gained weight in an
OFC trial, who complained of akathisia in an aripiprazole trial, or
who reported sedation in a quetiapine trial would likely cue the
awareness of study personnel that they were assigned to the active
drug condition. Assuming that proper informed consent was
obtained, participants were also likely to accurately guess their
treatment assignment based on side effect cues [68,69]. This could
have led to inflated efficacy ratings by clinical raters and
participants [70,71]. The lack of protocols assessing the integrity
PLOS Medicine | www.plosmedicine.org
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We found that after meeting criteria for remission, OFC-treated
participants were more likely to relapse than placebo-treated
participants; this contributed to our finding a less favorable result
for OFC in terms of remission. Second, we extracted data from all
comparison groups that received adjunctive placebo treatment,
whereas Nelson and Papakostas excluded one comparison group
from each of two OFC trials [25,26]. Third, Nelson and Papakostas
estimated a significant treatment effect for OFC on response,
whereas we did not. This difference seems due to a combination of
our inclusion of all adjunctive placebo comparison groups and our
use of random effects analysis as opposed to their use of a fixed
effects model [38]. Our fourth point of difference was that Nelson
and Papakostas included data from two conference presentations on
quetiapine that showed positive findings; we were unable to obtain
data from these authors despite three emailed requests over a span
of 4 wk. Additionally, we attempted to contact one author via
phone; the attempt did not result in the release of any data.
Nonetheless, the pooled ORs generated in our analyses for
quetiapine in terms of response (1.53) and remission (1.79) were
quite similar to those published in Nelson and Papakostas’s metaanalysis (1.60 and 1.89, respectively). Our fifth difference was the
use of different definitions of remission in one risperidone trial [73],
and the sixth difference was Nelson and Papakostas’s inclusion of
data from one small risperidone trial from which we were unable to
extract remission data [77], leading to our finding a slightly lower
rate of remission (OR of 2.37 versus 2.63). Lastly, and most
importantly, the primary point of difference is that our analysis
provides a more comprehensive appraisal of treatment efficacy and
safety, which, as discussed above, presents a more accurate
assessment of the comparative risks and benefits of treatment.
Our review adds to the Cochrane review on this topic [9] by
filling in three important data gaps: (1) unpublished data from the
FDA and clinical trial registry reports, (2) data on functioning and
quality of life outcomes, and (3) data on metabolic laboratory
parameters. Thus, our dataset contained more outcomes and often
provided a more comprehensive assessment of included outcomes
than the Cochrane review. For instance, the Cochrane review
included data from one trial that reported data on clinically
significant weight gain for patients on OFC, whereas we included
data on both mean weight changes and binary measures of clinically
significant weight gain from four such trials. We included laboratory
data for several metabolic parameters for both quetiapine and OFC.
Despite some differences in methodology, we agree with the
Cochrane review that the evidence supporting the use of adjunctive
atypical antipsychotics for depression is modest.
Several methodological issues also bear mention. First, while all
trials were described as randomized, double-blind trials, only three
trials clearly described adequate sequence generation procedures;
in the remaining studies, such procedures were unclear. A lack of
appropriate randomization or differences in the taste, smell, or
appearance of the medication and placebo may allow study
personnel and/or participants to guess their treatment assignment.
As purportedly double-blind trials with unclear or inadequate
randomization are associated with larger effects than trials in
which adequate randomization is clearly described, this leads to

the possibility that the current set of efficacy ratings were inflated
to an unknown extent [21,78]. Second, the design of some of the
included trials may have compromised their validity. In each of the
aripiprazole trials, patients were treated with an antidepressant
plus adjunctive placebo for 8 wk; at that point, those who showed
a treatment response were eliminated from the study, and the
remaining patients were assigned to either remain on the same
treatment or receive adjunctive aripiprazole in place of adjunctive
placebo. Thus, all patients taking placebo during the randomized
trial had clearly demonstrated poor response to placebo treatment
and were likely predisposed to perform poorly during the
randomized portion of the trial, thereby possibly inflating the
estimated efficacy of the study drug [79].
In any systematic review, publication bias is a potentially serious
problem [10,80]. To incorporate as much data as possible, we
conducted a thorough literature search and included unpublished
data. We did not uncover the existence of any additional
unpublished negative trials in our search, but this does not mean
that such trials do not exist. Given the small number of trials for
each drug in our study, we lacked statistical power to conduct a
formal analysis of publication bias for each drug. However, when
pooling across drugs, we detected that publication bias may have
slightly enhanced the overall effect size on depression measures.
Our results likely represent an upper boundary for the efficacy of
these compounds (as demonstrated in prior meta-analyses),
assuming that relevant unpublished data are more negative than
positive in terms of efficacy [10,11].
We are aware of no trials that have directly compared
adjunctive atypical antipsychotic medication treatment to other
adjunctive treatments such as psychotherapy or lithium, or to
other treatment strategies such as switching the antidepressant
medication initially used for treatment. Further study may answer
critical outstanding questions regarding the safety profiles and
longer-term outcomes associated with these medications. Taken
together, our meta-analysis found evidence of (1) some improvement in clinician-assessed depressive symptoms, (2) little evidence
of substantial benefit in overall well-being, and (3) abundant
evidence of potential treatment-related harm. Our comprehensive
evaluation of safety and both relative and absolute efficacy
provides critical insight that may be useful for clinicians attempting
to thoroughly understand the risk–benefit profiles of these
adjunctive treatments for major depressive disorder.
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Editors’ Summary
NNT was 19; for all the other drugs it was nine. All the drugs
except OFC also significantly improved response rates
(defined as a 50% improvement in depression rating score).
However, the medications provided little or no benefit in
terms of functioning and quality of life, except for risperidone, which had a small-to-moderate effect on quality of life.
Finally, treatment with atypical antipsychotic medications
was linked to several adverse effects, including weight gain
(all four drugs) and akathisia (aripiprazole).

Background Everyone feels miserable occasionally. But for
people who are clinically depressed, feelings of sadness and
hopelessness and physical symptoms such as sleeping badly
can last for months or years and can make them feel life is no
longer worth living. Depression affects one in six people at
some time during their life. Clinicians diagnose depression
by asking their patients a series of questions about their
feelings and symptoms. The answer to each question is
given a score, and the total score from the questionnaire
(‘‘depression rating scale’’) indicates the severity of depression. Treatment of depression often involves talking treatments (psychotherapy) such as cognitive behavioral therapy,
which helps people change negative ways of thinking and
behaving and antidepressant drugs, most commonly ‘‘selective serotonin reuptake inhibitors’’ such as fluoxetine and
paroxetine.

What Do These Findings Mean? These results suggest
that atypical antipsychotic medications for the adjunctive
treatment of depression are efficacious in reducing observerrated depressive symptoms. However, clinicians should
interpret this conclusion cautiously for several reasons. First,
adjunctive treatment with atypical antipsychotics provided
only small-to-moderate benefits. Moreover, shortcomings in
study design and data reporting methods may have inflated
the apparent benefits of treatment and reduced the
apparent incidence of adverse events. Second, this study
provides little evidence that adjunctive treatment with
atypical antipsychotics improves patients’ quality of life or
reduces their functional impairment. Finally, this study
highlights abundant evidence of potential treatment-related
harm. This evaluation of the safety and efficacy of adjunctive
treatments for clinical depression provides critical insights
that should help clinicians better understand the risk–benefit
profiles of this approach to the treatment of major
depressive disorder.

Why Was This Study Done? Atypical antipsychotic
medications (for example, aripiprazole, olanzapine/fluoxetine
combination [OFC], quetiapine, and risperidone) are also
widely prescribed for the treatment of depression. These
drugs, which were developed to treat mental illnesses that
are characterized by a loss of contact with reality, are used as
adjunctive therapy for depression. That is, they are used in
addition to antidepressant drugs. Clinicians wrote nearly four
million prescriptions for adjunctive treatment of depression
with atypical antipsychotic medications in 2007–2008 in the
US alone. However, it is not known whether the benefits of
using these drugs to treat depression outweigh their side
effects, which include weight gain, sedation, and akathisia (a
feeling of inner restlessness resulting in an urge to move,
which may or may not be accompanied by increased
movement). Here, the researchers undertake a systematic
review and meta-analysis of the efficacy and safety profiles of
atypical antipsychotic medications used for the adjunctive
treatment of depression. A systematic review uses predefined criteria to identify all the research on a given topic; a
meta-analysis is a statistical approach that combines the
results of several studies.

Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001403.
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What Did the Researchers Do and Find? The researchers
identified 14 short-term randomized controlled trials (duration 4–12 weeks) that compared adjunctive antipsychotic
medications (aripiprazole, OFC, quetiapine, or risperidone) to
placebo (dummy drug) in the treatment of depression that
had not responded to antidepressant medication alone. All
four drugs had statistically significant effects (effects unlikely
to have happened by chance) on remission, which was most
commonly defined as a score of less than eight at the study
end point on the Montgomery–Asberg Depression Rating
Scale. The researchers calculated the number of patients that
would have to be treated for one patient to achieve
remission (number needed to treat, or NNT). For OFC, the
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The US National Institute of Mental Health provides
information on all aspects of depression (in English and
Spanish); it has a webpage on mental health medications
that includes information about atypical antipsychotics
The UK National Health Service Choices website also
provides detailed information about depression and
includes personal stories about depression
More personal stories about depression are available from
healthtalkonline.org
The UK charity Mind provides information on depression
and on antipsychotic drugs; Mind also includes personal
stories about depression on its website
MedlinePlus provides links to other resources about
depression (in English and Spanish)
Healthy Skepticism is an international nonprofit membership association that aims to improve health by reducing
harm from misleading health information
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